Non-alcoholic fatty liver disease

The Inner Circle Acknowledges, David Chua, M.D., FASGE as a Distinguished Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Monday, October 30, 2023
House at 200 West North Avenue, Colitis, American College, Mouth, Endoscopy, Gastrointestinal tract, University of Santo Tomas Faculty of Medicine and Surgery, ACG, Rush University, Pancreas, American Board of Commissioners for Foreign Missions, Wayne State University, Liver, American College of Gastroenterology, Society, Non-alcoholic fatty liver disease, Lincoln Park, Medical degree, Colonoscopy, Human, Inner circle, NASH, Wayne, Medical specialty, American Society for Gastrointestinal Endoscopy, IBS, Internal, University, Love, Peptic ulcer disease, Gastrointestinal Endoscopy, Hepatitis, Therapeutic endoscopy, Patient, Parent, Pharmaceutical industry, Gastroenterology, Crohn's disease, Medicine

OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • Dr. Chua pursued a Medical Degree from the University of Santo Tomas Faculty of Medicine and Surgery.
  • He is considered an expert in colonoscopy, liver, hepatitis, Crohns, and IBS and Therapeutic Endoscopy.
  • Board certified by the American Board of Internal Medicine-Internal Medicine, and Gastroenterology by the American Board of Internal Medicine- Internal Medicine and Gastroenterology.

SUMMIT CLINICAL RESEARCH (THE LEADING INTEGRATED RESEARCH ORGANIZATION IN THE MASH FIELD) TO PRESENT LEADING EDGE INSIGHTS AT THE AASLD LIVER MEETING FROM OVER 6,000 PATIENTS ACROSS MULTIPLE CLINICAL TRIALS

Retrieved on: 
Monday, October 30, 2023
FDA, NIT, Hynes Convention Center, DSM-IV codes, Physician, Health, Research, AM, Summit, Clinical trial, Steatosis, Atherosclerosis Risk in Communities, Disease, NASH, Fibrosis, SCR, Hepatology, MASH, Audubon Ballroom, Metabolism, SAN, AASLD, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Aluminium, Patient, Non-alcoholic fatty liver disease, Medicine

The research, focusing on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related subjects contains significant findings derived from therapeutic trials involving over 6,000 patients.

Key Points: 
  • The research, focusing on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related subjects contains significant findings derived from therapeutic trials involving over 6,000 patients.
  • Dr. Harrison, Founder and Chairman of Summit Clinical Research; Founder and Chairman of Pinnacle Clinical Research, commented: "Summit Clinical Research is a beacon in the MASH arena.
  • The presentations at the AASLD Liver Meeting highlight the critical role of continued research in liver diseases and metabolic disorders.
  • Summit Clinical Research is honored to significantly contribute to these efforts and share our insights with the medical community.

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Thursday, October 26, 2023
Fast track (FDA), FDA, Food, Obesity, Fast Track, Liver transplantation, Diabetes, Fibrosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASH, Liver failure, NAFLD, Safety, Patient, Non-alcoholic fatty liver disease, Pharmaceutical industry, IMPACT

GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of NASH.

Key Points: 
  • GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of NASH.
  • NASH is a serious, potentially life-threatening condition that is a leading cause of liver failure and liver transplantation globally.
  • NASH is a growing public health concern, and there are currently no approved treatments.
  • The Fast Track designation is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and address unmet medical needs.

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 25, 2023
University of Oxford, Obesity, Hepatology, Fibrosis, Inflammation, American Association for the Study of Liver Diseases, NASH, Fatty liver disease, NAFLD, Non-alcoholic fatty liver disease, AASLD, Pharmaceutical industry

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023).

Key Points: 
  • GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023).
  • Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
  • Details for the presentation are as follows:
    Pemvidutide-induced liver fat reduction in subjects with non-alcoholic fatty liver disease correlate with improvements in non-invasive markers of inflammation and fibrosis: Results of a 24-week multicenter, randomized, double-blind, placebo-controlled trial
    Dr. Stephen Harrison, Medical Director, Pinnacle Research, and Adjunct Professor of Medicine, Oxford University
    The late-breaking poster will be made available on the Events section of the Altimmune website at the time of the presentation.

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Retrieved on: 
Thursday, October 19, 2023
Patient, FDA, Publication, Therapy, UDCA, Hepatology, Cirrhosis, ELF, Safety, Liver, Fibrosis, Primary sclerosing cholangitis, Idiopathic pulmonary fibrosis, Liver disease, Inflammation, HIV disease progression rates, IPF, PSC, Pharmacokinetics, Ursodeoxycholic acid, American Association for the Study of Liver Diseases, Disease, EMA, Liver failure, Integrin, Toronto Centre, Abstract, Inflammatory bowel disease, Non-alcoholic fatty liver disease, SAN, AASLD, Pharmaceutical industry, Vaccine, Medical imaging

The oral presentation titled “Oral αvβ6/αVβ1 Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease.

Key Points: 
  • The oral presentation titled “Oral αvβ6/αVβ1 Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease.
  • PSC is a rare, progressive liver disease of unknown origin, which frequently occurs in the setting of inflammatory bowel disease.
  • PSC is characterized by inflammation and fibrosis, with progressive liver and biliary damage leading to cirrhosis and liver failure.
  • Exploratory endpoints will measure changes in liver fibrosis markers, ELF and PRO-C3, liver biochemistry and liver imaging.

AMRA Medical’s MRI-based Biomarkers Validated in the FNIH’s NIMBLE Study

Retrieved on: 
Wednesday, October 25, 2023
Diabetes, Technology, Radiology, Surgery, Oncology, General Health, Medical Devices, Hospitals, Fitness & Nutrition, Clinical Trials, Other Technology, Cardiology, Biotechnology, Science, Research, Health, Patient, Abdominal cavity, MRI, Biomarker, Obesity, Type, Disease, Multimedia, CVD, Non-alcoholic fatty liver disease, NASH, Risk, Medicine, T2D, Bangladesh Technical Education Board, NAFLD, Body composition, Insulin resistance, VAT, Adipose tissue, Diagnosis, Fatty liver disease, Cardiovascular disease, Cirrhosis, Medical imaging

This study validates, prospectively, the precision and repeatability of AMRA Medical’s VAT biomarker for use in clinical trials.

Key Points: 
  • This study validates, prospectively, the precision and repeatability of AMRA Medical’s VAT biomarker for use in clinical trials.
  • AMRA Medical´s VAT biomarker was chosen as one of the primary biomarkers in the NIMBLE 1.2 study, showing excellent repeatability in patients with NAFLD.
  • The NIMBLE 1.2 study was designed to assess the potential of using MRI-based biomarkers longitudinally in NAFLD/NASH clinical trials.
  • Data on other body composition biomarkers and metrics from AMRA have also been collected and will be reported in a future paper.

Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Retrieved on: 
Friday, October 13, 2023
Weight gain, BMI, ID, Senior, TSX, Enzyme inhibitor, HIV, Massachusetts General Hospital, Adipose tissue, Connective tissue, Hospital, VAT, FDA, Person, HFF, Harvard Medical School, NAFLD, Assistant, Non-alcoholic fatty liver disease, Body mass index, Patient, Pharmaceutical industry, Medicine

MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data in a poster session at ID Week 2023 in Boston, Mass., demonstrating that treatment with tesamorelin significantly reduced visceral adipose tissue (VAT) and hepatic fat fraction (HFF, a measure of liver fat) in people with HIV treated with integrase inhibitor (INSTI) based regimens.

Key Points: 
  • In the retrospective sub-analysis, tesamorelin reduced VAT by 8.3% after 12 months of treatment, compared to a 10.8% increase in VAT among placebo-treated patients treated with INSTIs (p=0.0034).
  • Furthermore, the tesamorelin group experienced a 31% relative reduction in HFF compared to a 0% reduction for the placebo group at 12 months (p=0.006).
  • That finding prompted the latest analysis, in which investigators reviewed data from a previous placebo-controlled trial of 61 patients with HIV-associated non-alcoholic fatty liver disease (NAFLD).
  • “Tesamorelin remains the only FDA-approved therapy to treat excess abdominal fat in adults with HIV, and these data are yet another key piece in highlighting its efficacy in modern HIV management.”

Marathon Runners Take to the Windy City to Raise Awareness of Liver Disease

Retrieved on: 
Wednesday, October 4, 2023
Chicago Marathon, Travel, University, ALF, University of Michigan, Life, Liver disease, Grant Park, American Liver Foundation, Primary sclerosing cholangitis, Research, Liver cancer, MHS, Running, MD, Patient, Physician, Non-alcoholic fatty liver disease, Gambat Liver Transplant Center, Bank, Team, Dietary supplement

FAIRFIELD, N.J., Oct. 4, 2023 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Bank of America Chicago Marathon Official Charity Program for the 2023 race, which takes place on Sunday, October 8, 2023, in iconic Grant Park.

Key Points: 
  • "There are nearly 100 million people in the U.S. affected by liver disease, and most aren't aware they even have it.
  • That's why we are so honored that these runners have chosen to join us to help raise awareness and funds to combat liver disease."
  • The American Liver Foundation's Bank of America Chicago Marathon team has already met their fundraising goal and has since increased it.
  • The American Liver Foundation team is made up of runners with varying levels of experience from novice to advanced, most of whom have a connection to liver disease.

October is National Liver Awareness Month, Are You at Risk?

Retrieved on: 
Friday, September 29, 2023
Learning, AstraZeneca, Fatty liver disease, Partnership, Obesity, ALF, Diet, NASH, Genetics, Liver disease, Liver cancer, Non-alcoholic fatty liver disease, American Liver Foundation, Research, Inflammation, Education, Federally Qualified Health Center, Patient, Cooking, Risk, Liver, Knowledge, NAFLD, BMI, Hispanic, Liver failure, Conference, Caregiver, Dietary supplement

FAIRFIELD, N.J., Sept. 29, 2023 /PRNewswire/ -- October is National Liver Awareness Month and the American Liver Foundation is encouraging everyone to find out if they are at risk for fatty liver disease through its public awareness campaign, Think Liver Think Life™. Fatty liver disease affects an estimated 80-100 million Americans and is present in up to 75% of overweight people and in more than 90% of people with severe obesity. Through a simple liver health quiz, available at ThinkLiverThinkLife.org in both English and in Spanish, anyone can find out if they're at risk and learn what to do next.

Key Points: 
  • FAIRFIELD, N.J., Sept. 29, 2023 /PRNewswire/ -- October is National Liver Awareness Month and the American Liver Foundation is encouraging everyone to find out if they are at risk for fatty liver disease through its public awareness campaign, Think Liver Think Life™.
  • "This October, we encourage everyone to do something positive for your liver by taking our free liver health quiz ," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • The Think Liver Think Life national public health campaign aims to ensure every American understands their risk for liver disease, receives the appropriate diagnostic testing and care coordination and feels well-informed and supported throughout their liver journey.
  • Nonalcoholic steatohepatitis (NASH) is a form of NAFLD causing inflammation of the liver and liver damage, which can lead to liver failure.

Inventiva reports its 2023 first-half financial results and provides a corporate update

Retrieved on: 
Thursday, September 28, 2023
Diabetes, European, SEC Rule 144A, August 31, American depositary receipt, Jefferies, Type 2 diabetes, Regulation D, G&A, Investigational New Drug, Patient, University, Risk, NAFLD, EIB, NASH, TD, Pharmacokinetics, Virtual, Research, USD, Non-alcoholic fatty liver disease, Council, Security (finance), Phase, Kidney, IND, NMPA, Conference, Data monitoring committee, Biotechnology, US, ATM, DSM-IV codes, Depreciation, Acceleration, European Parliament, ADS, Exchange, Person, Sale, Prospectus, T2D, Pharmaceutical industry, Lithium, Bank, Cryptocurrency, Medical device, Medical imaging, Audit, EU

General and administrative expenses (G&A) amounted to €6.8 million in the first half of 2023, stable compared to the first half of 2022.

Key Points: 
  • General and administrative expenses (G&A) amounted to €6.8 million in the first half of 2023, stable compared to the first half of 2022.
  • The Company’s net loss stood at (€55.3) million as of June 30, 2023 compared to (€29.5) million as of June 30, 2022.
  • R&D expenses for the first half of 2023 were up 81% compared to the first half of 2022.
  • The conference call and the slides of the presentation will be webcast live at https://edge.media-server.com/mmc/p/5tuhsaud and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.